BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38561831)

  • 1. Advancing Hepatitis C Elimination through Opt-Out Universal Screening and Treatment in Carceral Settings, United States.
    McNamara M; Furukawa N; Cartwright EJ
    Emerg Infect Dis; 2024 Apr; 30(13):S80-S87. PubMed ID: 38561831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont.
    Hale AJ; Mathur S; Dejace J; Lidofsky SD
    Public Health Rep; 2023; 138(2):265-272. PubMed ID: 35264027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
    Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
    J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination.
    Spaulding AC; Adee MG; Lawrence RT; Chhatwal J; von Oehsen W
    Infect Dis Clin North Am; 2018 Jun; 32(2):323-345. PubMed ID: 29778259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of hepatitis C virus infection among incarcerated persons: Results from the Louisiana Hepatitis C Elimination Plan's opt-out testing program in prisons.
    Irvin R; Landry G; Jones MR; James A; Schexnayder J; Rodriguez S; Wendell D; Barthe K; Britton E; LeSar K; Manogue S; Sugarman OK; Brown C; Burgess S; Mehta SH; Thomas DL; Robinson W;
    J Viral Hepat; 2024 Jul; 31(7):432-435. PubMed ID: 38758571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
    He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
    Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States.
    Chhatwal J; Chen Q; Bethea ED; Hur C; Spaulding AC; Kanwal F
    Aliment Pharmacol Ther; 2019 Jul; 50(1):66-74. PubMed ID: 31115920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pragmatic Experience with Risk-based versus Universal Hepatitis C Screening in Pregnancy: Detection of Infection and Postpartum Linkage to Care.
    Bushman ET; Subramani L; Sanjanwala A; Dionne-Odom J; Franco R; Owen J; Subramaniam A
    Am J Perinatol; 2021 Sep; 38(11):1109-1116. PubMed ID: 33934324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micro-elimination of hepatitis C through testing of Egyptian pregnant women presenting at delivery: implications for screening policies.
    Mostafa A; Ebeid FSE; Khaled B; Ahmed RHM; El-Sayed MH
    Trop Med Int Health; 2020 Jul; 25(7):850-860. PubMed ID: 32306545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investing in Community Care Is an Important Goal and Need for Eliminating Hepatitis C in the United States: An Abolitionist Perspective.
    Bhatnagar P; Canzater SL
    Health Promot Pract; 2023 May; 24(3):411-414. PubMed ID: 36305488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities for Enhanced Prevention and Control of Hepatitis C Through Improved Screening and Testing Efforts.
    Cartwright EJ; Patel PR
    J Infect Dis; 2024 May; 229(Supplement_3):S350-S356. PubMed ID: 37739791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C.
    Sulkowski M; Cheng WH; Marx S; Sanchez Gonzalez Y; Strezewski J; Reau N
    Adv Ther; 2021 Jan; 38(1):423-440. PubMed ID: 33145648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV spread among female incarcerated population and treatment pathways to viral elimination in Italian prison settings: clinical perspectives and medico legal aspects.
    Fiore V; Rastrelli E; Madeddu G; Ranieri R; De Vito A; Giuliani R; Di Mizio G; Bolcato M; De Matteis G; Ialungo AM; Dell'Isola S; Starnini G; Babudieri S
    BMC Infect Dis; 2022 Jul; 22(1):601. PubMed ID: 35799126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovations in Hepatitis C Screening and Treatment.
    Patel AA; Bui A; Prohl E; Bhattacharya D; Wang S; Branch AD; Perumalswami PV
    Hepatol Commun; 2021 Mar; 5(3):371-386. PubMed ID: 33681673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute searching and early diagnosis of HCV infected persons.
    Husa Ml P; Husa P
    Vnitr Lek; 2021; 67(8):455-458. PubMed ID: 35459364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Securing sustainable funding for viral hepatitis elimination plans.
    Hatzakis A; Lazarus JV; Cholongitas E; Baptista-Leite R; Boucher C; Busoi CS; Deuffic-Burban S; Chhatwal J; Esmat G; Hutchinson S; Malliori MM; Maticic M; Mozalevskis A; Negro F; Papandreou GA; Papatheodoridis GV; Peck-Radosavljevic M; Razavi H; Reic T; Schatz E; Tozun N; Younossi Z; Manns MP
    Liver Int; 2020 Feb; 40(2):260-270. PubMed ID: 31808281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
    Tsertsvadze T; Gamkrelidze A; Chkhartishvili N; Abutidze A; Sharvadze L; Kerashvili V; Butsashvili M; Metreveli D; Gvinjilia L; Shadaker S; Nasrullah M; Adamia E; Zeuzem S; Afdhal N; Arora S; Thornton K; Skaggs B; Kuchuloria T; Lagvilava M; Sergeenko D; Averhoff F
    Clin Infect Dis; 2020 Aug; 71(5):1263-1268. PubMed ID: 31563938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
    Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
    World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.